DAFNA Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

DAFNA Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,000	Closed	-$210K	–	92
2019 Q3	$210K	Buy	20,000 +17,000	+567%	+$222K	0.08%	82
2019 Q2	$51K	Hold	3,000	–	–	0.02%	86
2019 Q1	$101K	Hold	3,000	–	–	0.04%	77
2018 Q4	$88K	Hold	3,000	–	–	0.04%	80
2018 Q3	$185K	Hold	3,000	–	–	0.08%	73
2018 Q2	$221K	Buy	+3,000	New	+$234K	0.1%	72
2018 Q1	–	Sell	-2,000	Closed	-$168K	–	82
2017 Q4	$168K	Hold	2,000	–	–	0.09%	70
2017 Q3	$231K	Hold	2,000	–	–	0.14%	63
2017 Q2	$234K	Hold	2,000	–	–	0.17%	65
2017 Q1	$247K	Buy	+2,000	New	+$262K	0.21%	64

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAFNA Capital Management's BLCM Position: Q4 2019 in Review

DAFNA Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2019, closing a stake of 20,000 shares — an estimated $210K sold.

DAFNA Capital Management first reported a position in BLCM in Q1 2017 and held it in 10 quarters. The position peaked at $247K in Q1 2017. 51 funds tracked by Wall St. Rank hold BLCM as of Q4 2019.

DAFNA Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
DAFNA Capital Management sold 20,000 Bellicum Pharmaceuticals, Inc. shares in Q4 2019, an estimated $210K.
DAFNA Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 10 quarters.
DAFNA Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $247K in Q1 2017.
51 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2019.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.